ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1888

PU.1, Mitf, and Their Novel Co-Partner, Eomes, Set up a Transcription Factor Network That Is Critical for Osteoclast Differentiation

Heather Carey1, Sankha Ghosh1, Eason Hildreth III2, Jennifer Cabrera1, Dias Kurmashev1, Wael N. Jarjour3, Ramiro Toribio2, Sudarshana Sharma1 and Michael Ostrowski1, 1Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH, 2Veterinary Clinical Sciences, The Ohio State University, Columbus, OH, 3Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: genomics, osteoclastogenesis, osteoclasts and transcriptional regulation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics, Genomics and Proteomics I: Epigenetic Mechanisms in Autoimmunity

Session Type: Abstract Submissions (ACR)

Background/Purpose

Osteoclasts are bone resorbing cells which differentiate from myeloid precursors. The crosstalk between osteoblasts and osteoclasts tightly regulates the dynamic and continuous process of bone remodeling. Deregulation of this delicate balance is implicated in osteoporosis pathology. A variety of transcription factors including PU.1, MITF, NFATc1, and cFOS are essential for osteoclast differentiation. However, the interplay between these factors is not fully defined. We have previously shown that the transcription factors MITF and PU.1 act as a complex to regulate multiple genes required for osteoclast function. This study was designed to understand the global transcriptional regulatory processes involved in osteoclast differentiation.

Methods

We examined transcriptional regulation of target genes by MITF and PU.1 in myeloid precursors and osteoclasts using ChIP-Seq to map the genome-wide binding of these factors. In parallel, microarray analysis was performed to monitor target gene expression changes over the course of differentiation. We also queried the sequences jointly bound by PU.1 and MITF to search for conserved binding sequences potentially indicating novel co-partners in osteoclasts. We used micro-computed tomography and histological analysis to examine the effects of myeloid lineage-specific and osteoclast-specific deletion of PU.1 and its copartners in vivo and in vitro. 

Results

ChIP-Seq and microarray profiling revealed that MITF and PU.1 jointly regulate the transcription of over 1000 genes in developing osteoclasts. Most of the MITF/ PU.1 co-bound regions were found in distal enhancer-like elements at the same sites in both myeloid precursors and osteoclasts. Overlap of our ChIP-Seq and microarray data sets utilizing Gene Set Enrichment Analysis (GSEA) revealed that transcription factor genes were the only subset significantly enriched in genes with PU.1/ MITF co-bound regions. These transcription factors include NFATc1, c-FOS, and NFKB, which are already known to be essential for osteoclast differentiation. Additionally, 38% of genomic regions jointly bound by PU.1 and MITF in developing osteoclasts contained the binding motif of the T-box transcription factor EOMES. Conventional ChIP assays validated binding of EOMES to MITF/PU.1 bound regions. Micro-computed topography analysis of murine bone has demonstrated that the loss of PU.1 or EOMES in osteoclasts and their myeloid precursors leads to a severe osteopetrotic phenotype in neonatal mice due to highly deficient osteoclast differentiation and function.

Conclusion

Our results demonstrate that MITF and PU.1 set up a transcription factor regulatory network in myeloid precursors which triggers osteoclast differentiation in response to cues from the bone microenvironment. Ablation of PU.1 or its novel copartner EOMES results in disruption of this transcription factor network and therefore halts the differentiation program.


Disclosure:

H. Carey,
None;

S. Ghosh,
None;

E. Hildreth III,
None;

J. Cabrera,
None;

D. Kurmashev,
None;

W. N. Jarjour,
None;

R. Toribio,
None;

S. Sharma,
None;

M. Ostrowski,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pu-1-mitf-and-their-novel-co-partner-eomes-set-up-a-transcription-factor-network-that-is-critical-for-osteoclast-differentiation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology